Jimmie Varnado, MD
Family Medicine · Greensburg, LANPI 1114976867
Payments from drug & device makers
Across 144 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$786
- AbbVie$584
- Pfizer$286
- Takeda Pharmaceuticals U.S.A., Inc.$229
- Boehringer Ingelheim$161
- GSK$137
- plus $648 from 11 others
What the payments were for
- Food & beverage$2,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $786 |
| AbbVie(2 entities) | 35 | $584 |
| Pfizer | 15 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $229 |
| Boehringer Ingelheim | 3 | $161 |
| GSK | 8 | $137 |
| Abbott | 1 | $125 |
| Novartis | 7 | $124 |
| Bayer | 3 | $98 |
| Lilly USA, LLC | 5 | $85 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Merck | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$126
- CardioMEMS HF System$125
- JARDIANCE$125
How this compares
$2,832 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $131,114 |
| JanuviaSitagliptin Phosphate | 177 | $122,139 |
| EliquisApixaban | 174 | $99,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $86,764 |
| JardianceEmpagliflozin | 89 | $72,226 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 69 | $69,285 |
| OzempicSemaglutide | 59 | $65,771 |
| LinzessLinaclotide | 104 | $61,245 |
| TrulicityDulaglutide | 29 | $32,854 |
| XareltoRivaroxaban | 43 | $27,323 |
| VraylarCariprazine Hcl | 14 | $19,797 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $11,804 |
| TradjentaLinagliptin | 21 | $11,606 |
| FarxigaDapagliflozin Propanediol | 12 | $11,012 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $10,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $85 | $163,968154 claims |
| MerckJanuvia | $43 | $122,139177 claims |
| PfizerEliquis, Premarin | $286 | $101,958190 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $161 | $95,636134 claims |
| GSKTrelegy Ellipta | $137 | $86,764112 claims |
| AbbVieLinzess, Vraylar, Combigan | $584 | $84,044132 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $79 | $69,28569 claims |
| Johnson & JohnsonXarelto | $14 | $27,32343 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $16 | $3,304106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Greensburg
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.